Advances in the Treatment of Metastatic Colorectal Cancer

被引：32

作者：

Kurkjian, Carla ^{[2
]}

Kummar, Shivaani ^{[1
]}

机构：

[1] NCI, Med Oncol Branch, Clin Res Ctr, Bethesda, MD 20892 USA

[2] Univ Oklahoma, Dept Hematol Oncol, Oklahoma City, OK USA

来源：

AMERICAN JOURNAL OF THERAPEUTICS | 2009年 / 16卷 / 05期

关键词：

colorectal; cancer; metastatic treatment; GROWTH-FACTOR RECEPTOR; FLUOROURACIL PLUS LEUCOVORIN; III COLON-CANCER; HIGH-DOSE LEUCOVORIN; GENE COPY NUMBER; CONTINUOUS-INFUSION; 1ST-LINE TREATMENT; ORAL CAPECITABINE; RANDOMIZED-TRIAL; PHASE-III;

D O I：

10.1097/MJT.0b013e3181907ed9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The treatment of metastatic colorectal cancer has undergone major advances yielding significant improvements in survival over the past decade. These advances have evolved due to the benefits of combination chemotherapy and the incorporation of biologic therapy. However, as we struggle to provide optimum care while sparing patients ineffective therapy and undue cost, the importance of tailored therapy to maximize benefit will become increasingly important. This article reviews the major advances in the treatment of patients with metastatic colorectal cancer and the burgeoning developments in individualized therapy.

引用

页码：412 / 420

页数：9

共 70 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[3] Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen [J].

André, T ;

Louvet, C ;

Raymond, E ;

Tournigand, C ;

de Gramont, A .

ANNALS OF ONCOLOGY, 1998, 9 (11) :1251-1253

[4] Determinants of RASistance to anti-epidermal growth factor receptor agents [J].

Baselga, Jose ;

Rosen, Neal .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1582-1584

[5] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[6] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

De Braud, F. G. ;

Volovat, C. ;

Nippgen, J. ;

Stroh, C. ;

Celik, I. ;

Koralewski, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[7]

BOS JL, 1989, CANCER RES, V49, P4682

[8] 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OF METASTATIC COLORECTAL-CANCER - A RANDOMIZED COMPARISON - A SOUTHWEST ONCOLOGY GROUP-STUDY [J].

BUDD, GT ;

FLEMING, TR ;

BUKOWSKI, RM ;

MCCRACKEN, JD ;

RIVKIN, SE ;

OBRYAN, RM ;

BALCERZAK, SP ;

MACDONALD, JS .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (02) :272-277

[9] EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients [J].

Cappuzzo, F. ;

Finocchiaro, G. ;

Rossi, E. ;

Jaenne, P. A. ;

Carnaghi, C. ;

Calandri, C. ;

Bencardino, K. ;

Ligorio, C. ;

Ciardiello, F. ;

Pressiani, T. ;

Destro, A. ;

Roncalli, M. ;

Crino, L. ;

Franklin, W. A. ;

Santoro, A. ;

Varella-Garcia, M. .

ANNALS OF ONCOLOGY, 2008, 19 (04) :717-723

[10] A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer [J].

Cheeseman, SL ;

Joel, SP ;

Chester, JD ;

Wilson, G ;

Dent, JT ;

Richards, FJ ;

Seymour, MT .

BRITISH JOURNAL OF CANCER, 2002, 87 (04) :393-399

← 1 2 3 4 5 6 7 →